Paul Edick ’77 has joined Sucampo Pharmaceuticals, Inc. board of directors on August 1. He brings extensive experience to this global biopharmaceutical company, as he has been a consultant in the pharmaceutical and healthcare industry for 35 years.
In a GlobeNewswire press release, Peter Greenleaf, chairman and chief executive officer of Sucampo, welcomed Edick, saying, “Paul is a well-rounded and seasoned chief executive with a depth of experience in building and leading specialty pharmaceutical companies. With the addition of Paul, we have assembled a world-class board of directors with the experience to help Sucampo execute our growth strategy focused on diversification of our portfolio of commercial and development-stage products.”
Edick has had a successful career within this industry; he held senior-level positions working at GD Searle & Company and was the group vice president and president for Asia and Latin America at Pharmacia Corporation. He held the position of CEO of Ganic Pharmaceuticals, Inc. as well as at MedPointe Healthcare, Inc. Additionally, he was formerly the CEO and board member of Durata Therapeutics, Inc. Edick is now a chairman of the board of Iterum Therapeutics and a director for PDL BioPharma, Inc., NewLink Genetics, Inc. and Neos Therapeutics, Inc. He is also the founding partner of 3G Advisors.
At Hamilton, Edick majored in psychology, was on the men’s swimming and diving team and was a member of the fraternity Delta Upsilon.
